For research use only. We do not sell to patients.
Ionizable lipids / Lipid Trp-L1-T4
Lipid Trp-L1-T4 chemical structure
Product imageResearch use only
CAT. NO. DC68057Featured

Lipid Trp-L1-T4

Ionizable lipid for LNP and nucleic-acid delivery research.

Research highlights
Tfh-cell-competent saRNA deliveryCXCR5-targeted CAR-Tfh researchSustained CAR and Foxp3 expressionPreclinical autoimmune-hepatitis model
Derived from the cited study; not a product specification or performance guarantee.

Pack size & price

USD
Supporting components
Cholesterol DCD-041 · 100 mg+DMG-PEG2000 DC40169 · 100 mg+DOPE DC33634 · 100 mg

Components are supplied separately; this is not a premixed LNP. RNA/cargo, buffer and formulation service are not included.

TotalUS$750
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended
Product overview

Description & Application

Trp-L1-T4 is an L-tryptophan-derived ionizable lipid selected as the core lipid in the study's TLNP platform for self-amplifying RNA delivery to follicular helper T cells. The base TLNP formulation produced 59.8% GFP-positive primary Tfh cells under the reported in vitro conditions. In targeted variants, the authors combined CXCR5-antibody functionalization, Tfh-restricted RNA translation and, for in vivo work, Tween-20 modification to generate regulatory CAR-Tfh cells and evaluate a preclinical autoimmune-hepatitis model. These outcomes depend on the complete formulation, targeting ligand, RNA design and study conditions. All formulation and performance information shown below is literature-derived evidence, not a product specification or a guarantee of reproducible LNP performance.

CAS No.Not available
Chemical NameLipid Trp-L1-T4
SynonymsTrp-L1-T4, Trp L1 T4, Trp-L1T4, TLNP ionizable lipid
SMILESCCCCCCCCCCCCCCN(CCCCCCCCCCCCCC)CCNC(=O)[C@@H](N)Cc1c[nH]c2ccccc12
FormulaC41H74N4O
M.Wt639.07
Purity>95% by ELSD-HPLC
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
PublicationZheng Z, Liu Y, Wang G, et al. In vivo CAR-Tfh cell reprogramming restores tolerance in a mouse model of autoimmune hepatitis. Cell Stem Cell. 2026;33:589-604.

Literature-reported formulation composition

ComponentReported molar ratioRole
Trp-L1-T425Ionizable lipid
Cholesterol20Sterol
DMG-PEG20000.5PEG lipid
DOPE10Helper phospholipid
Reported ratio sum55.5Original ratio retained

Formulation weight calculator

The cited formulation and available component molecular weights are pre-filled. Enter the exact molecular weight for any substituted material before calculating.

The source reports a non-normalized molar ratio with a sum of 55.5. The calculator normalizes these ratios only for component-weight calculation.
ComponentMolecular weight (g/mol)Literature molar ratio
Trp-L1-T4
Cholesterol
DMG-PEG2000
DOPE
Calculated component requirements
ComponentNormalized mol%Amount (µmol)Required weight (mg)
Total100.000%——

Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.

Not reported in the cited article
10:1 ionizable lipid:saRNA (w/w) in the main text; Supplementary Figure S1D labels the optimized axis as total lipids:mRNA, creating a terminology ambiguity
10 mM citrate aqueous phase, pH 3; post-mixing dialysis against PBS
GFP self-amplifying RNA (saRNA)
In vitro Tfh-cell transfection for the lead TLNP result; targeted therapeutic variants were given intravenously
80 ng GFP-saRNA per 50,000 Tfh cells
Primary mouse follicular helper T cells for lead screening
Staggered-herringbone microfluidic mixing at 3:1 aqueous:ethanol flow-rate ratio; 2 h dialysis through a 10 kDa membrane, concentration with a 100 kDa filter and 0.22-micrometer filtration; stored at 4 degrees C.

Literature-reported performance for the cited formulation

Literature-reported59.8%24 h after 80 ng GFP-saRNA per 50,000 cells · Selected as the lead dose with minimal cytotoxicityMain text, printed p. 592 / PDF p. 5; Supplementary Figure S1H,I
Literature-reported107.0 ± 13.4 nmPost-formulation characterization · UFC-TLNPSupplementary Table S2, SI PDF p. 12
Literature-reported0.16 ± 0.05Post-formulation characterization · UFC-TLNPSupplementary Table S2, SI PDF p. 12
Literature-reported-1.9 ± 1.5 mVPost-formulation characterization · UFC-TLNPSupplementary Table S2, SI PDF p. 12
Literature-reported85.28 ± 3.56%Post-formulation characterization · UFC-TLNPSupplementary Table S2, SI PDF p. 12

Additional reported findings

CAR and Foxp3 coexpression

UFC-TLNP produced a reported 59.0% CAR-positive and Foxp3-positive Tfh-cell population.

Tfh cells; UFC-saRNA; in vitro · Main Figure 2B, PDF p. 4
Targeted regulatory-phenotype persistence

After UFC-RLNP treatment, the reported Foxp3-positive Tfh fractions were 60.6% on day 1, 56.4% on day 3, 51.9% on day 7 and 49.2% on day 14.

CXCR5-antibody-functionalized RLNP; n=3; in vitro · Main Figure 3B,C, PDF p. 6
Tfh versus conventional T-cell expression

At 24 h, UFC-RLNP produced 61.3% DeltaLNGFR-positive Tfh cells versus 1.44% conventional T cells in the reported assay.

Tfh-restricted UFC-saRNA translation plus CXCR5-targeted uptake; n=3 · Main Figure 3I,J
Preclinical autoimmune-hepatitis study

A single UFC-Tw/RLNP dose improved reported biochemical, immune and liver-histology endpoints in both prophylactic and established Ad-2D6 autoimmune-hepatitis-II mouse experiments relative to saline controls.

Female C57BL/6J mice; 5 micrograms saRNA IV on day 1 or day 28; preclinical evidence only · Main Figures 6-7 and Supplementary Figures S6-S7
Reported experimental tolerability

The authors reported no detectable red-blood-cell lysis in the tested assay, no significant Tfh cytotoxicity at tested in vitro doses, stable body weight and no treatment-associated abnormality in examined major-organ H&E sections.

Assay- and mouse-study-specific observations; not a formal toxicology program · Main Figure 2M; Supplementary Figures S1, S2G, S6A and S7G
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetZheng Z, Liu Y, Wang G, et al. In vivo CAR-Tfh cell reprogramming restores tolerance in a mouse model of autoimmune hepatitis. Cell Stem Cell. 2026;33:589-604. DOI: 10.1016/j.stem.2026.02.006
Structure and lead selection: main Figure 1 and Supplementary Figure S1; base formulation: main text and Supplementary Table S1; preparation: STAR Methods; particle properties: Supplementary Table S2; targeted CAR-Tfh performance and mouse AIH-II studies: main Figures 2-7 and Supplementary Figures S2-S7.
Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg15.6477 mL3.1295 mL1.5648 mL
25 mg39.1193 mL7.8239 mL3.9119 mL
50 mg78.2387 mL15.6477 mL7.8239 mL
100 mg156.4774 mL31.2955 mL15.6477 mL
250 mg391.1935 mL78.2387 mL39.1193 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.